Should Linezolid Replace Clindamycin for Necrotizing Soft Tissue Infections?
October 27th 2023A comparative study found that using linezolid in place of clindamycin in combination with vancomycin for the treatment of necrotizing soft tissue infections resulted in similar 30-day mortality rates but lower rates of acute kidney injury and composite adverse outcomes, suggesting the effectiveness and safety of linezolid as an alternative therapy.
Moderna Begins Phase 3 Trial for its Influenza-COVID-19 Vaccine
October 26th 2023The company dosed its first study participant with its investigational vaccine, mRNA-1083. And this follows recent data reported from their phase 1/2 trial where the vaccine showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile.
Understanding the Risk of Infection Associated With Neutrophils and Alcohol-Related Hepatitis
October 24th 2023With increased neutrophils during alcohol-related hepatitis, patients experience an increased risk of infection due to the impaired function of the neutrophils. A new study looks to uncover the mechanisms for which this hepatitis impacts the body.
This Week's Infectious Disease News
October 22nd 2023This week's news included a new study that showed the association with Epstein-Barr virus reactivation and sets the need for an antiviral clinical trial with cardiopulmonary exercise testing as an endpoint; a clinician weighs in on the limited use of novel, gram-negative antibiotics; and the discussion around increasing hepatitis C testing for the pediatric population.
2 Year Data on Lenacapavir Reinforces Clinical Profile for Adults With Multi-Drug Resistant HIV
October 21st 2023The antiretroviral, lenacapavir (Sunlenca 463.5 mg/1.5 mL injection), had reported resistance in only a minority of study participants according to the latest findings released at a conference.